Mikhail Blagosklonny is a scientist who focuses on cancer and aging studies. This outstanding scientist has an MD in internal medicine and a Ph.D. in experimental medicine and cardiology. He got his honors for the First Pavlov State Medical University of St. Petersburg. Mikhail Blagosklonny is interested in research that includes cancer and is more targeted at cancer therapies that may provide protection from damaging the healthy cells. He has also done some remarkable research on the study of the underlying processes that lead to aging; this also entails the research into drugs that may help to stop or just slow down the aging process entirely.
In 2002, Mikhail Blagosklonny served the New York Medical College after he was appointed as the associate professor. He then went ahead to take a role as the senior scientist at Ordway Research Institute. Mikhail continued with his tenure at Ordway Research Institute until 2009. This was the year when he got an appointment as the professor at Roswell Park Cancer Institute.
Mikhail has formulated a theory in the possible role of TOR signaling in fighting cancer and the adverse effects of aging. He has suggested the use of a drug called rapamycin to possibly deal with old age. Rapamycin is a popular cancer drug that Mikhail Blagosklonny has passionately advocated for in longevity research. He is also the editor-in-chief at Aging. This is a monthly open access medical journal that is peer-reviewed. Aging is published by Impact Journals. It primarily covers research on senescence gerontology as well as the molecular mechanisms of aging.
Mikhail Blagosklonny is the editor-in-chief at Cell Cycle. This is a biweekly scientific journal that is reviewed by peers and is centered on cell biology. He is the editor-in-chief at Oncotarget too, another open access peer-reviewed medical journal that covers research on the aspects of oncology. He is known for having authored over 200 articles in these peer-reviewed journals. Mikhail is also the Associate Editor at Cancer Res, Autophagy, Cancer Biol Ther, Cell Death Differ, Int. J Cancer, PLOS ONE and Am J Pathology.
Mikhail has made some remarkable contributions in the research into fields of molecular and cellular biology. He is also known for his clinical investigations inclusive of cell cycle, signal transduction, cellular senescence and anti-cancer therapeutics primarily centered on the translation of the basic science into modern anti-cancer strategies. Of late he has extended signal transduction pathways study from cancer to include aging. Mikhail has revealed potential objectives for slowing down aging and the adverse effects that come along with it.